Key statistics
As of last trade, Kalvista Pharmaceuticals Inc (4XC1:FRA) traded at 10.20, 47.83% above the 52 week low of 6.90 set on Nov 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.20 |
---|---|
High | 10.20 |
Low | 10.20 |
Bid | 10.40 |
Offer | 10.70 |
Previous close | 10.10 |
Average volume | 0.00 |
---|---|
Shares outstanding | 49.08m |
Free float | 48.46m |
P/E (TTM) | -- |
Market cap | 560.02m USD |
EPS (TTM) | -3.54 USD |
Data delayed at least 15 minutes, as of Nov 11 2024 07:39 GMT.
More ▼
Press releases
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million
- KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust
- KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology
- KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
- KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum
- KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema
- KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)
- KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
- KalVista Appoints Brian Piekos as Chief Financial Officer
More ▼